Calaspargase Pegol (Asparlas)

Abstract

CADTH recommends that Asparlas be reimbursed by public drug plans as a component of a multiagent chemotherapeutic (MAC) regimen for the treatment of acute lymphoblastic leukemia (ALL) in pediatric and young adult patients age 1 to 21 years if certain conditions are met. Asparlas should only be covered to treat children and young adults with ALL. Asparlas should only be reimbursed as part of a MAC regimen. Asparlas should be prescribed by clinicians with expertise in the management of ALL, and the cost of Asparlas should not exceed the drug program cost of treatment with pegaspargase.